fosun pharma establishes suzhou innovation r&d center
[15 november 2017, hong kong] on november 14, shanghai fosun pharmaceutical (group) co.,ltd. (referred to as “fosun pharma”) (stock code: 600196.sh, 02196.hk) and the suzhou industrial park management committee (referred to as “suzhou industrial park administrative committee”) signed the “strategic cooperation agreement”. both parties had reached consensus on strategic cooperation in regard to fosun pharma suzhou innovation r&d center (referred to as “innovative research and development center”). this strategic cooperation would be rewarding as fosun pharma would integrate its existing industrial resources with the industrial nurturing and developmental environment in suzhou industrial park. it would also strengthen the construction of innovation r&d platform in the eastern coastal areas and further enhance the original innovation and transformation capabilities of end products from r&d.
innovation r&d center began to operate within biomedical industrial park, suzhou in november 2017. as of 14 november 2017, fosun orinove (suzhou) pharmatech, inc. (referred to as “fosun orinove “), wanxin pharmaceutical technology (suzhou) co., ltd. (referred to as “wanxin pharmaceutical”) and cmic (suzhou) pharmaceutical technology (suzhou) co., ltd. (referred to as “cmic pharmaceutical”) had all relocated to theinnovation r&d center.
according to the “strategic cooperation agreement”, as a major technological innovation incubation platform of fosun pharma, the innovation r&d center would primarily focus on original innovation and r&d, and would introduce pharmaceutical innovation r&d enterprises sponsored by fosun pharma. in addition, fosun pharma would initiate industrialization of pharmaceutical products, in alignment with the pace of development in industrial innovation and r&d, and regulatory controls imposed in the industrial park. suzhou industrial park administrative committee would render details of relevant policies and actively support the developments of suzhou innovation r&d center.
xu huimin, a member of suzhou municipal committee and the party committee secretary of suzhou industrial park, expressed that the establishment of suzhou innovation r&d center in suzhou industrial park will induce new impetus and vitality to fosun pharma’s leading edge in innovation and r&d. at the same time, suzhou industrial park would strive to provide more supporting policies, enhanced functional facilities and highly efficient pro-business services to facilitate the development of fosun pharma. also, they would sincerely work with fosun pharma to seize the great opportunity set forth by the 19th national congress in implementing the strategy for a healthy china, to create a better future through more collaborations, within a broader spectrum.
"in the future, through high efficiency in innovation and value-based management model, innovation r&d center will attain value maximization in innovation, and r&d. the center will further enhance the value of suzhou industrial park in the areas of platform construction, products’ value-added and industrialization," said shao ying, the vice president of fosun pharma, senior vice president of fosun pharma industry corporation and director of fosun pharmaceutical industry research institute.
wu yifang, president and ceo of fosun pharma, said that fosun pharma would always regards innovation as the driving force for its business growth. in the future, fosun pharma would continue to explore and practice in three different aspects: first, to make more efforts to promote the establishment of partnerships in innovation and r&d, in order to drive the global exploitation of cutting-edge products; second, to strengthen innovative cooperation with the world's outstanding enterprises; third, to adhere to enhancing our own whole-chained r&d and post-industrialization developmental capabilities. fosun pharma is keen to becoming an exemplar of china’s high-end enterprise in the global pharmaceutical industry. it would continue to initiate innovation and collaborate in advancing the innovation capacity of china's pharmaceutical for the benefits of patients worldwide.